Phase 4 N=101 Skin and Soft Tissue Infection (SSTI) Study
Skin Diseases, Infectious · Soft Tissue Infections
Primary: Number of Participants With a Clinical Cure — 45; 42 Participants — p=0.71
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=1,077 Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
Skin/Soft Tissue Infections · Methicillin Resistant Staphylococcus Aureus (MRSA)
Primary: Clinical Outcome in Participants With Baseline Methicillin-Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for Per-Protocol (PP) Population — 84.1; 79.9…
Phase 2 N=1,310 Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Staphylococcal Infection
Primary: Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population. — 89.5; 88.2; 92.9; 92.7 percentage of…
Phase 3 N=2,265 Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"
Staphylococcal Infection
Primary: Number of Participants With Clinical Cure as of the Test-of-Cure (TOC) Visit in the Per Protocol Population — 457; 487; 182; 187 participants
N/A N=57,837 INSPIRE Trial for Skin and Soft Tissue Infections
Skin and Soft Tissue (SST) Infection
Primary: Extended-Spectrum Days of Antibacterial Therapy (ES-DOT) Per Empiric Day — 43305; 40156; 43927; 30287 Extended-Spectrum Days-of-Therapy
Phase 3 N=23 Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage
Abscess
Primary: Number of Participants With Abscess Resolution — 11; 9 Participants
Phase 3 N=679 Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections
Acute Bacterial Skin and Skin Structure Infections
Primary: Early Clinical Response — 306; 303 Participants
N/A N=31 Trial of Antibiotic Treatment for Skin Abscess in Patients at Risk for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection
Abscess
Primary: Clinical Improvement at 7 Days After Incision and Drainage — 10; 14 participants
N/A N=139 Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection
Abscess · Methicillin-Resistant Staphylococcus Aureus Infection
Primary: Recurrence Rates of Abscesses — 4; 14 participants
N/A N=25 Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections
Fasciitis, Necrotizing · Severe Necrotizing Skin and Soft Tissue Infections · Fournier's Gangrene
Primary: Clinical Response to High Dose Daptomycin Therapy at End of Treatment (EOT) — 16; 0; 2; 0 Participants
Phase 4 N=100 Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections
Cellulitis · Skin Infections
Primary: Satisfaction of Discharge Criteria — 15; 14 participants
Phase 4 N=161 Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management
Skin Diseases, Infectious
Primary: Skin Abscess Resolution — 4; 3 participants
N/A N=4 Evaluating the Use of Large-dose, Extended Interval Vancomycin Intravenous Administration for Skin and Soft Tissue Infections
Skin and Soft Tissue Infections
Primary: Clinical Efficacy — 2; 0 participants
Phase 4 N=396 Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections
Skin Diseases, Infectious
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 36.1; 36.8; 23.3; 18.4 percentage of participants
N/A N=30,209 Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees
Staphylococcus Aureus · MRSA Skin Infections · Staphylococcal Skin Infections
Primary: Incidence of Skin and Soft Tissue Infection (SSTI) — 303; 439; 461 participants
Phase 3 N=212 Prospective Randomized Trial of Bactrim on 7 Day Outcome in Patients With Uncomplicated Abscesses
Abscesses
Primary: Treatment Failures at 7 Days — 15; 27 participants
Phase 3 N=660 Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Skin and Subcutaneous Tissue Bacterial Infections
Primary: Objective Response at 48 to 72 Hours (FDA Primary Endpoint) — 259; 266; 72; 63 Participants
Phase 2 N=122 Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Infections, Bacterial
Primary: Number of Participants With Composite of the Cure Rate as Measured by Clinical Response and Outcome at the Early Efficacy Visit Combined With Withdrawal Rate — 48; 28…
Phase 3 N=850 Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Skin and Subcutaneous Tissue Bacterial Infections · Skin Structures and Soft Tissue Infections
Primary: Objective Response of ≥20% Reduction in Lesion Erythema Area Compared to Baseline at 48 to 72 Hours After Initiation of Treatment as Determined by Digital Measurements…
Phase 3 N=939 Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
Staphylococcal Skin Infection
Primary: Clinical Response — 358; 364; 59; 57 patients
Phase 2 N=201 Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
Infections, Gram-positive Bacterial
Primary: Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) Population — 74; 72; 3; 5 participants — p=0.5318
Phase 4 N=91 Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Bacterial Infections · Acute Bacterial Skin and Skin Structure Infection
Primary: Number of Infection-related Total Admitted Hospital Days — 4.8; 3.2 Days — p=0.003
Phase 3 N=968 Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)
Wound Infection · Abscess · Systemic Inflammation
Primary: Cessation Of Spread Or Reduction In Size Of Baseline Lesion, Absence Of Fever, And No Rescue Antibiotic Medication At Early Clinical Evaluation (ECE) (48 To 72 Hours)…
Phase 3 N=761 Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
Complicated Skin and Soft Tissue Infection
Primary: Clinical Response at Test of Cure (TOC) in Modified Intent-to-treat (MITT) Analysis Set — 396; 202; 58; 34 Participant
Phase 3 N=862 Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
Staphylococcal Skin Infection
Primary: Clinical Response — 323; 321; 52; 58 participants
Phase 2 N=120 TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection
Skin and Subcutaneous Tissue Bacterial Infections · Gram-Positive Bacterial Infections
Primary: Early Clinical Response at the Early Assessment (EA) Visit in the Intent-to-Treat (ITT) Population — 61; 27; 4; 3 Participants
Phase 4 N=313 Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Acute Bacterial Skin and Skin Structure Infections
Primary: Hospital Admission Rate at Initial Episode of Care — 60; 27; 96; 126 Participants — p=<0.001
Phase 4 N=249 Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA
Staphylococcal Skin Infections
Primary: Infection-Related Hospital Length of Stay — 91.46; 93.23 Hours
Phase 3 N=573 Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Abscess · Wound Infection · Surgical Site Infection
Primary: Early Clinical Efficacy — 240; 233; 48; 52 participants
Phase 3 N=739 Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Abscess · Wound Infection · Surgical Site Infection
Primary: Early Clinical Efficacy — 285; 288; 86; 80 participants